Related Experiment Video
Updated: Feb 10, 2026
09:01
Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
8.6K
Anticoagulation Resumption After Intracerebral Hemorrhage
Yan-Guang Li1,2, Gregory Y H Lip3,4,5
1Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, England, UK.
Current Atherosclerosis Reports
|May 22, 2018
Summary
Resuming oral anticoagulation after intracerebral hemorrhage (ICH) does not increase recurrent ICH risk and may reduce mortality. Careful risk assessment is crucial for deciding when to restart anticoagulation therapy.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Intracerebral hemorrhage (ICH) patients are often excluded from clinical trials, leading to uncertainty regarding anticoagulation management.
- Decision-making on resuming oral anticoagulants (OACs) after ICH is complex and debated among clinicians.
Purpose of the Study:
- To provide a comprehensive summary of current evidence on OAC resumption after ICH.
- To guide clinical decision-making in balancing risks and benefits of anticoagulation post-ICH.
Main Methods:
- This is a review article synthesizing existing evidence.
- Analysis of risks associated with OAC cessation versus resumption after ICH.
Main Results:
- OAC resumption after ICH does not elevate the risk of recurrent ICH.
- Stopping OACs increases the risk of thromboembolism, which OAC resumption can mitigate.
- Reduced all-cause mortality is associated with OAC resumption.
Conclusions:
- Optimal timing for OAC resumption post-ICH remains undetermined, requiring careful individual risk assessment.
- Newer anticoagulants and interventions offer alternatives, but high-quality evidence is lacking.
- A proposed management approach aids clinicians in deciding on OAC appropriateness, timing, and method of resumption.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K